[A preliminary study on SLAMF6 expression in patients with severe aplastic anemia]

Area of Science:

• Immunology
• Hematology
• Cell Biology

Background:

• Severe aplastic anemia (SAA) is a rare bone marrow failure disorder.
• The role of T-cell subsets, particularly CD8(+) T cells, in SAA pathogenesis is increasingly recognized.
• SLAMF6 (Signaling Lymphocytic Activation Molecule Family member 6) is a receptor expressed on lymphocytes, potentially involved in immune regulation.

Purpose of the Study:

• To investigate the expression levels of SLAMF6 on CD8(+) T cells in patients with SAA.
• To determine the correlation between SLAMF6 expression and the immune status and hematopoietic function in SAA patients.
• To elucidate the functional impact of SLAMF6 on CD8(+) T cell activity.

Main Methods:

• Flow cytometry was used to quantify SLAMF6 expression on peripheral blood CD8(+) T cells in 21 SAA patients and 15 healthy controls.
• Correlations were analyzed between SLAMF6 levels and hematological parameters (HGB, PLT, etc.), bone marrow cell percentages, and CD8(+) T cell effector molecules (perforin, granzyme B, IFN-γ).
• In vitro experiments involved blocking the SLAMF6 pathway using anti-SLAMF6 antibody to assess its effect on CD8(+) T cell effector functions.

Main Results:

• SLAMF6 expression on CD8(+) T cells was significantly lower in untreated SAA patients compared to normal controls (56.29% vs. 80.96%).
• Lower SLAMF6 expression in SAA patients positively correlated with hematopoietic parameters but negatively correlated with bone marrow lymphocyte percentage and CD8(+) T cell effector molecule expression.
• Blocking SLAMF6 significantly increased the production of perforin, granzyme B, and IFN-γ by CD8(+) T cells in SAA patients.

Conclusions:

• SLAMF6 is significantly downregulated on CD8(+) T cells in patients with severe aplastic anemia.
• This downregulation suggests SLAMF6 may function as a negative immunoregulatory molecule in SAA.
• SLAMF6 appears to modulate CD8(+) T cell activity, potentially contributing to the pathogenesis of SAA by influencing effector molecule secretion.